AbbVie Inc Q3 2026 Earnings: Narrow Miss on Both EPS and Revenue
AbbVie Inc (ABBV) reported third-quarter 2026 earnings that fell short of Wall Street expectations on both earnings per share and revenue. The pharmaceutical giant posted adjusted EPS of $3.65 versus the consensus estimate of $3.68, representing a -0.71% surprise. Revenue came in at $16.99 billion, missing the $17.10 billion estimate by -0.65%.
AbbVie is a research-based biopharmaceutical company focused on developing and commercializing advanced therapies for complex and serious diseases. The company’s portfolio spans immunology, oncology, neuroscience, and eye care, with blockbuster drugs including Humira, Skyrizi, and Rinvoq driving the majority of its revenue.
Earnings Performance Shows Modest Shortfall
The $3.65 adjusted EPS represents a decline from the $3.89 reported in Q3 2025, marking a year-over-year decrease of 6.2%. This miss, while narrow at less than 1%, breaks a streak of three consecutive quarters where AbbVie exceeded analyst expectations. The revenue shortfall of $110.8 million suggests challenges in maintaining the company’s growth trajectory amid increased competition in key therapeutic areas.
Compared to the previous quarter, Q3 2026 revenue of $16.99 billion represents a sequential decline of 2.1% from Q2 2026’s $17.35 billion. This quarterly decline reflects typical seasonal patterns in pharmaceutical sales, though the magnitude was larger than historical averages for the company.
Immunology Portfolio Faces Biosimilar Pressure
AbbVie’s immunology segment, which includes flagship drug Humira, continues to face headwinds from biosimilar competition. Humira revenue declined 18.5% year-over-year to $3.2 billion in Q3 2026, compared to $3.93 billion in the same quarter of 2025. However, newer immunology assets Skyrizi and Rinvoq showed strong growth, with combined revenue reaching $4.8 billion, up 24.3% from the prior year period.
The oncology portfolio delivered $1.9 billion in revenue, representing 8.7% growth year-over-year, driven by strong performance from Imbruvica and Venclexta. Gross margin for the quarter came in at 78.2%, down 120 basis points from the prior year due to product mix shifts and increased manufacturing costs.
Forward Guidance and Market Reaction
AbbVie maintained its full-year 2026 adjusted EPS guidance range of $14.40 to $14.60, suggesting confidence in fourth-quarter performance despite the Q3 miss. The company also reaffirmed its revenue guidance of $67.5 billion to $68.5 billion for the full year, implying Q4 revenue of approximately $17.8 billion at the midpoint.
Management highlighted $2.1 billion in research and development expenses for the quarter, up 12.4% year-over-year, reflecting continued investment in the company’s pipeline of 90+ programs across various therapeutic areas. The company’s cash position remained strong at $8.7 billion, supporting ongoing dividend payments and share repurchase activities.
In after-hours trading, AbbVie shares declined 2.3% following the earnings release, reflecting investor disappointment with the dual miss on key metrics. The stock had gained 8.4% year-to-date prior to the earnings announcement, outperforming the broader pharmaceutical sector average of 5.1%.
This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research and consult with financial advisors before making investment decisions.